Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 846 results for "Novartis Company"

Board of Novartis India approves resignation of company secret...

This page uses frames, but your browser doesn't Capital Market, 18 hours ago

111 images for Novartis Company

CTV News, 1 week ago
Business Insider, 1 week ago
Reuters India, 1 week ago
Reuters UK, 1 week ago
Yahoo! Singapore, 2 weeks ago
CTV News, 1 week ago
Domain-B, 4 days ago
SAMAA TV, 1 week ago
StatNews.com, 1 week ago
Irish Times, 1 week ago

Novartis India Q1 net at Rs 19 cr

The company had posted a net profit of Rs 13.34 crore for the corresponding period of the previous fiscal, Novartis India said in a filing on BSE.
 Money Control1 day ago Novartis India net jumps by 43% in Q1, buyback offer of share at Rs.760 each  PharmaBiz1 day ago Novartis India Q1 net at Rs 19 crore  Business Standard1 day ago Novartis India Q1 Net Profit At Rs 19 Crore  NDTV1 day ago
[x]  

Novartis India's board meeting on July 28, 2016

Novartis India Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on July 28, 2016, inter alia, to consider unaudited financial results of the Company for first quarter ended June 30, 2016.
 Money Control1 week ago Novartis India Ltd to approve Q1 results on July 28, 2016  Equity Bulls1 week ago Novartis India: Outcome of board meeting  Money Control1 day ago Novartis India's AGM on July 29, 2016  Money Control1 month ago

FDA lifts clinical hold on CGF166

GenVec, a clinical-stage gene delivery company, was notified by its collaborator, Novartis, that the Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 1/2 clinical trial of CGF166 in patients with severe to profound ...
 Pharmaceutical Business Review3 days ago BRIEF-Genvec says FDA lifts hold on clinical trial of hearing loss treatment  Reuters UK4 days ago GenVec announces US FDA lifts clinical hold on phase 1/2 trial of CGF166 in patients with severe to profound hearing loss  PharmaBiz2 days ago
[x]  
Fortune

Amgen Finally Scores a Win in Its Big Copycat Drug Battle With Novartis

Shares of Novartis nvs remained relatively flat Tuesday as the company announced second-quarter earnings hadn't fallen as much as expected. But in a blow, the Swiss pharma giant also revealed that regulators have rejected one of its experimental ...
 Fortune1 week ago Earnings Watchlist: Novartis AG (NYSE:NVS)  Markets Daily6 days ago Novartis AG (NVS) Issues Earnings Results, Beats Estimates By $0.05 EPS  SleekMoney1 week ago Novartis AG (NVS) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS  Mideast Time1 week ago
Reuters India

FDA knocks back Novartis copy of Amgen's drug Neulasta

The logo of Swiss pharmaceutical company Novartis is seen on its headquarters building in Basel, Switzerland October 27, 2015. Reuters/Arnd Wiegmann/File Photo U.S. regulators have declined to approve Novartis' so-called biosimilar copy of ...
 Reuters India1 week ago U.S. FDA knocks back Novartis copy of Amgen's drug Neulasta  Yahoo! Finance1 week ago
[x]  
Business Recorder

Novartis plans to invest $200 million this year to increase sales of heart failure medication

Novartis plans on spending an additional $200 million this year to boost sales of sacubitril/valsartan (Entresto), the company's twice-daily oral medication to treat patients with heart failure. During the second quarter of 2016, Novartis ...
 Cardiovascular Business1 week ago Novartis warns of profit decline as company plans to boost spending on heart-failure drug Entresto  FirstWord Pharma1 week ago Novartis fears 2016 earnings may fall on higher spending  The Gulf Today1 week ago Novartis warns 2016 profit may fall on higher heart drug spending  Sharenet1 week ago
[x]  
India Infoline

Novartis India to turn ex-date for buyback

Shares of Novartis India may remain in focus, as they will turn ex-date for the proposed buyback. The company plans to buy back 38.2 lakh shares (or 11.95 per cent of the total paid-up equity capital), from all the shareholders, including promoters, on a ...
 Business Line1 week ago Novartis India jumps 11% after share buyback plans  India Infoline2 months ago Novartis India Board to consider buyback of equity shares  India Infoline2 months ago
Financial Express

Novartis 2Q net profit slips

Swiss pharmaceuticals company Novartis says net profit from continuing operations dropped 3 per cent in the second quarter, largely because of new generic competition for its top cancer drug. The Basel-based giant reported on Tuesday that net ...
 NineMSN Finance1 week ago Novartis : 2Q net slips as generic drug competition hits sales  4 Traders1 week ago Novartis Q2 net slips as generic drug competition hits sales  Financial Express1 week ago Novartis 2Q net slips as generic drug competition hits sales  CTV News1 week ago

Novartis India tumbles as buyback plan disappoints investors

after the company's buyback plan disappointed investors. The company announced its buyback plan after market hours yesterday, 26 May 2016. Meanwhile, the S BSE Sensex was up 181.32 points or 0.69% at 26,550.90. More than usual volumes were witnessed on the ...
 Business Standard2 months ago Hit by dividend tax, firms opt for huge share buybacks  The Financial Chronicle3 weeks ago FDA nod for Strides Shasuns HIV drug and other top pharma news  India Infoline2 months ago Novartis India gallops as board to consider buyback  Business Standard2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less